top of page
vinnytsia-ukraine-december-28-2017-offset-printing-process-ready-newspaper-print-mashine.j

DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.

EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

PUBLICATIONS

Publications

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.

STUDY

OFFICIAL TITLE

DISEASE

JOURNAL/
CONGRESS

YEAR

DOWNLOAD

Publications

PATHFINDER

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

Breast

Breast Cancer Research

2025

PATHFINDER
Publications

ATRACTIB

 Atezolizumab plus paclitaxel and bevacizumab as first-line treatment 1 of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 

Breast

Nature Medicine

2025

ATRACTIB
Publications

TUXEDO-3

Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: results from the TUXEDO-3 phase II trial   

BREAST, LUNG AND LMS

ASCO

2025

TUXEDO-3
Publications

PARSIFAL LONG

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial  

Breast

ESMO Open

2025

PARSIFAL LONG
Publications

PALMIRA

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial

BREAST

(Journal) Journal of Clinical Oncology

2025

PALMIRA
Publications

ADELA

Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

BREAST

ASCO

2025

ADELA
Publications

LUPER

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study

Lung

Journal of Thoracic Oncology

2025

LUPER
Publications

TUXEDO-3 (cohort 3)

Patritumab deruxtecan (HER3-DXd) in leptomeningeal metastatic disease of solid tumors: results from a prospective phase II trial 

Leptomeningeal disease from any solid tumor

Nature Medicine

2025

TUXEDO-3 (cohort 3)
Publications

TRANSFAL

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial

Breast

NPJ Breast

2025

TRANSFAL
Publications

TUXEDO-4

TUXEDO-4: Phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases

Breast

Future Oncology

2025

TUXEDO-4
Publications

CT1/T2CN0 PHERGAIN substudy

Clinical outcomes in patients (pts) with stage cT1/T2cN0 HER2[+] breast cancer (BC) treated with neoadjuvant trastuzumab and pertuzumab (HP): An exploratory analysis from the PHERGain trial 

Breast

ESMO Breast

2025

CT1/T2CN0 PHERGAIN substudy
Publications

PRIMED

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative 3 advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

Breast

eClinicalMedicine

2025

PRIMED
Publications

Other MEDSIR related articles

home_fondo_cuadritos2.jpg
"
WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.
bottom of page